Ossur Hf : Q3 Results 2015

Ossur Hf : Q3 Results 2015

ID: 428984

(Thomson Reuters ONE) -


Announcement from Össur hf. no: 41/2015



Highlights Q3 2015

* Sales amounted to USD 117 million compared to USD 127 million in Q3 2014.
Sales growth in local currency amounted to 3%.
* Bracing and supports sales growth was 5%, measured in local currency.
* Prosthetics sales growth was flat, measured in local currency, compared to a
strong quarter last year.
* Gross profit amounted to USD 74 million and 63% of sales, compared to USD
81 million and 64% of sales in Q3 2014.
* EBITDA amounted to USD 25 million or 22% of sales, compared to USD 29
million or 23% of sales in Q3 2014.
* Net profit amounted to USD 14 million or 12% of sales, compared to USD 16
million or 13% of sales in Q3 2014.
* USD strengthening has had a significant impact on reported sales and profits
when comparing to prior year results. It has negatively impacted sales by
USD 11 million and EBITDA by USD 2 million.
* Cash generated by operations amounted to USD 23 million or 20% of sales,
compared to USD 33 million or 26% of sales in Q3 2014.



Financial Guidance for 2015

The financial guidance for the full year of 2015 is unchanged:

* Total sales growth LCY in the range of 4-6%.
* Organic sales growth LCY in the range of 3-5%.
* EBITDA margin in the range of 20-21% of sales.
* Capital expenditures 3.5-4.5% of sales.
* Effective tax rate around 26%.



Jón Sigurðsson, President & CEO, comments:

"The results of the quarter are in line with expectations. As in previous
quarters there is an adverse impact from currency fluctuations. B&S sales were
good in all markets, driven by growth of high end innovative products.
Prosthetics growth was flat, however we are comparing to an exceptionally strong




quarter last year. At the end of the quarter we proudly announced a technical
update to our RHEO KNEE(®) 3 that entails enhanced features and weatherproof
design."

You can find all announcements from Össur on our website:
http://www.ossur.com/corporate/



Conference Call

Össur will host a conference call on Friday 23 October 2015 at 10:00 CET/ 8:00
GMT/ 4:00 EDT.

To participate in the call please dial:
Europe: + 45 3544 5579, +44 (0) 203 364 5374 or +46 (0) 8 505 564 74
The United States: + 1 855 753 2230
Iceland: +354 800 7417


Q3 2015 Company announcement:
http://hugin.info/133773/R/1960981/714972.pdf

Q3 2015 Investor presentation:
http://hugin.info/133773/R/1960981/714965.pdf



This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Ossur Hf via GlobeNewswire
[HUG#1960981]




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Novavax Initiates Phase 2 Safety and Immunogenicity Trial to Evaluate Annual Re-Dosing of the RSV F Vaccine in Older Adults Basilea announces that European Commission maintained isavuconazole's orphan drug status
Bereitgestellt von Benutzer: hugin
Datum: 22.10.2015 - 22:01 Uhr
Sprache: Deutsch
News-ID 428984
Anzahl Zeichen: 3439

contact information:
Town:

Reykjavik



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 230 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ossur Hf : Q3 Results 2015"
steht unter der journalistisch-redaktionellen Verantwortung von

Ossur Hf (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Ossur Hf



 

Werbung



Sponsoren

foodir.org The food directory für Deutschland
News zu Snacks finden Sie auf Snackeo.
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z